The Standard and Poor (SP) report of March 15, 1997 indicates that the stock beta is 2.67 which is higher than the Value Line (VL) beta of 1.40. Seems like analyst can't agree in terms of stock volatility. SP went from an avoid rating to hold. SP estimates Modafinil approval for end of 1997 and cautions that approval of Myotrophin is not guaranteed due to "controversy still swirls around Myotrophin's efficacy in treating ALS." You can obtain the SP report through your broker or order through some service. First Call puts earnings estimate (as of 3/12/97) for 1997 at $-2.82.
You make reference to the info I posted which was taken from currently files SEC reports and refer to it as quote:
>>SEC mumbo-jumbo that companies need to file in order to protect themselves>>
I thought the SEC reports by law have to be accurate or you had to pay big fines or went to Jail or both. I wonder what is mumbo jumbo, the SEC filing or your posting?
I only posted the SEC reprt to inform those who read the thread and gave them the way to verify the facts. You never point out where you get your info?
The info posted on the SEC filing was only coincidential because it occured at the same time I was doing research. The SEC filing is accurate and I would never invest in a company which product composition is in the public domain! It does not own the products patent and is open to competition from companies like Genetech. This is not Coca-Cola.
Your accuracy in ALS cases is mindboggling and impossible to verify. CEPH states about 20,000, SP states 25,000, an ALS help group states 35,000. Where did you get your figures and that level of accuracy?! What is the error of measurement? Nobody can quote a number with such accuracy !
>>Rilutek is far from being Myotrophin. It is hardly to be considered as competition to Myotrophin.>>
The fact is that Rilutek is approved for ALS by both the FDA and european agencies while Myotrophin is NOT! The effectiveness and safety of Rilutek is better than Myotrophin since it is FDA approved. Myotrophin has controversial results which did not permit CEPH to prove that it was safe nad effective, two critical FDA requirements. A tIND was granted for Myotrophin and was given due to political and patient pressure. That takes away the burden from the FDA and puts it on CEPH to prove that their product works!
The info posted on the SEC filing was only coincidential beacause it occured at the same time I was doing research. The SEC filing is accurate and I would never invest in a company which product composition is in the public domain! It does not have own the products patent and is open to competition. This is not Coca-Cola.
>>PROVIGIL is the ONLY non-amphetamine, non-addictive, virtually side effect free drug EVER for narcolepsy. >>
This needs to be proven and CEPH experience in products filing is limited. Cheak the SEC filings. CEPH has no approved product! Their clinical studies can be flawed and larger companies have had their NDA's not approved due to additional required studies.
Wake up, CEPH has been at this since August 1987, loosing money. $10,000 dollars invested 5 years ago is worth only $16,181 according to SP. I don't know what they were pedaling 10 years ago, maybe snake venom but they haven't been successful at it. They have been successful in getting their stock sold by underwriters who make "mucho $$$$$$" no matter what the stock does. The more they prop up the stock, the more sales! I am sorry that you have fallen victim to this marketing scheme.
>>Now it is in testing for ADD. It will blow away Ritalin. I did not see that ADD trial, which is currently started, on your Cephalon list.>>
The SEC info was provided by CEPH and did not mention ADD. Are you an insider or employee to know as a fact that the ADD studies are underway or are you just getting your info from some broker who will say anything? To blow away Ritalin will take time since effectiveness is not proven by some limited clinical studies. No other company snatched up Provigil which is a drug from some other company licensed to CEPH. Where can I find info of this great product currently marketed in europe for this orphan disease. Where is the link with ADD and the mechanism of action.
> |
